Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.
Saved in:
| Title: | Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program. |
|---|---|
| Authors: | Senna M; Lahey Hospital and Medical Center, Burlington, MA, USA., Hanna S; University of Toronto, Toronto, ON, Canada., Ueki R; Juntendo University, Tokyo, Japan., Zhang X; The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Aguh C; Department of Dermatology, Johns Hopkins Medicine, Baltimore, MD, USA., Piraccini BM; Piraccini Medical Center, Bologna, Italy., Wajsbrot D; Pfizer Inc, Groton, CT, USA., Nagy E; Pfizer Inc UK, Sandwich, Kent, UK., Sadrarhami M; Pfizer Inc, New York, NY, USA., Chen S; Pfizer Inc, New York, NY, USA., Wolk R; Pfizer Inc, Groton, CT, USA., Tran H; Pfizer Inc, New York, NY, USA., Lejeune A; Pfizer Inc, 23 Av. du Dr Lannelongue, 75014, Paris, France. alexandre.lejeune@pfizer.com. |
| Source: | American journal of clinical dermatology [Am J Clin Dermatol] 2026 Jul 22. Date of Electronic Publication: 2026 Jul 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1888 (Electronic) Linking ISSN: 11750561 NLM ISO Abbreviation: Am J Clin Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1179-1888 |
|---|---|
| DOI: | 10.1007/s40257-026-01062-x |
